✨ PRACTICE CHANGING ✨ data from #ESMO26

返回会议原文

返回会议

Ana I. Velázquez Mañana, MD, MSc, FASCO· @AnaVManana · X·2026-10-25 23:54· 1 天前评分70

正文 · 原文

✨ PRACTICE CHANGING ✨ data from #ESMO26

Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer

@FSkoulidis presents results from Krascendo 1

Divarasib significantly prolongs PFS and OS with a more tolerable safety profile

11 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Ana I. Velázquez Mañana, MD, MSc, FASCO · x.com